Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Lord Markham on 7 September (HL9841), whether they have any plans to discuss Vorasidenib with Servier Laboratories.

The Medicines and Healthcare products Regulatory Agency (MHRA) has not granted a marketing authorisation for Vorasidenib, however should an application be received from Servier Laboratories, the MHRA has licensing pathways available, with the aim of ensuring the products can be made available for patients in the United Kingdom in the shortest time possible and to support and protect public health. While the MHRA will assess any submitted applications and is willing to facilitate the appropriate regulatory processes, the agency cannot actively seek these applications and as such there are currently no plans to discuss Vorasidenib with Servier Laboratories.